Breaking News Instant updates and real-time market news.

MX

MagnaChip

$8.84

0.06 (0.68%)

, MAT

Mattel

$10.80

-0.25 (-2.26%)

18:58
06/11/19
06/11
18:58
06/11/19
18:58

Fly Intel: After Hours Movers

HIGHER: MagnaChip Semiconductor (MX) up 16.9% after raising Q2 revenue guidance... Mattel (MAT) up 8.2% after LA Times report regarding unsolicited offer for company from MGA Entertainment... Nuvectra (NVTR) up 7.3% after filing regulatory submission with FDA for Algovita SCS system... Medidata (MDSO) up 5.5% after Bloomberg report that company is near buyout by Dassault... CymaBay (CBAY) up 3.4% after being upgraded to Strong Buy at Raymond James... Tesla (TSLA) up 3.3% after upbeat comments by CEO Musk at Annual Shareholder Meeting. DOWN AFTER EARNINGS: Dave & Busters (PLAY) down 17.1%. ALSO LOWER: National Beverage (FIZZ) down 1.4% after being downgraded at CFRA Research. Movers as of 18:45ET.

MX

MagnaChip

$8.84

0.06 (0.68%)

MAT

Mattel

$10.80

-0.25 (-2.26%)

NVTR

Nuvectra

$3.96

0.155 (4.08%)

MDSO

Medidata

$94.75

3.97 (4.37%)

CBAY

CymaBay

$6.05

-5.035 (-45.44%)

TSLA

Tesla

$217.08

4.18 (1.96%)

PLAY

Dave & Buster's

$51.55

0.98 (1.94%)

FIZZ

National Beverage

$45.15

-2.3 (-4.85%)

  • 11

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 12

    Jun

  • 13

    Jun

  • 23

    Jun

  • 30

    Jul

MX MagnaChip
$8.84

0.06 (0.68%)

10/23/18
ROTH
10/23/18
NO CHANGE
Target $13
ROTH
Buy
MagnaChip price target lowered to $13 from $18 at Roth Capital
Roth Capital analyst Suji Desilva lowered his price target for MagnaChip to $13 from $18 ahead of quarterly results to reflect broader semiconductor stock weakness. The analyst reiterates a Buy rating on the shares.
MAT Mattel
$10.80

-0.25 (-2.26%)

10/26/18
JEFF
10/26/18
NO CHANGE
Target $13
JEFF
Hold
Jefferies says Mattel valuation 'still stretched,' cuts target to $13
At first glance, Mattel's earnings report "was in range," but unpacking the results uncovered a "more challenging set of facts" with sales down 10%, Jefferies analyst Stephanie Wissink tells investors in a post-earnings research note. She lowered her estimates for Mattel and dropped her price target for the shares to $13 from $14. The multiple at current share levels is " still stretched," says Wissink.
12/24/18
BMOC
12/24/18
NO CHANGE
Target $20
BMOC
Spin Master licensing deal with Warner negative for Mattel, says BMO Capital
BMO Capital analyst Gerrick Johnson says the Friday report of a DC superheroes licensing deal between Toys R Us Spin Master and Warner is a negative for Mattel. While the report has not been confirmed, the analyst believes that the business will be lost after 2019. Longer term, the analyst keeps his Outperform rating and $20 price target on Mattel and believes that its management "can facilitate needed changes in culture, product development, digital content, and partner relationships to drive sales and earnings growth."
02/08/19
MKMP
02/08/19
NO CHANGE
Target $15
MKMP
Neutral
Mattel price target raised to $15 from $12 at MKM Partners
MKM Partners analyst Eric Handler raised his price target on Mattel to $15 after its Q4 results surprised to the upside. The analyst also keeps his Neutral rating, noting that while the cost cuts have contributed to the earnings beat, the "revenue turnaround is still a work in progress".
02/26/19
BMOC
02/26/19
NO CHANGE
Target $20
BMOC
Outperform
Mattel price target lowered to $20 from $23 at BMO Capital
BMO Capital analyst Gerrick Johnson lowered his price target on Mattel to $20 after attending the company's Toy Fair analyst event. The analyst states that while he is "encouraged" by its efforts to reposition business toward profitable growth, the turnaround involving "SKU rationalization,process improvement, cost reduction, and infrastructure investments" could take longer than he anticipated. Longer term, Johnson keeps his Outperform rating on Mattel and believes that the stock still has "value that will continue to be unlocked" amid the management's transformation efforts.
NVTR Nuvectra
$3.96

0.155 (4.08%)

05/02/19
JMPS
05/02/19
NO CHANGE
Target $18
JMPS
Outperform
Nuvectra price target lowered to $18 from $26 at JMP Securities
JMP Securities analyst David Turkaly noted a few negative takeaways from Nuvectra's Q1 earnings call, foremost among them being news that the FDA has requested additional information as part of the pending PMA application for approval of its Virtis sacral nerve stimulation product and will collect supplementary data on the biocompatibility of the device's leads. While he believes Nuvectra shares are already trading at a depressed valuation and keeps an Outperform rating on the stock, Turkaly lowered his price target on shares to $18 to reflect the extended timeline on Virtis and his lowered 2020 sales estimate.
05/16/19
PIPR
05/16/19
NO CHANGE
PIPR
Overweight
Piper defends shares of Nuvectra after another executive leaves
Piper Jaffray analyst Matt O'Brien says he's continuing to defend shares of Nuvectra after another executive departed, this time COO and CFO Walter Berger. CEO transitions, like the one that just occurred at the company, are usually followed by additional executive departures, O'Brien tells investors in a research note. He does not believe the timing of Berger's departure and the recently amended Virtis timing are related. The analyst continues to believe Nuvectra has a strong spinal cord stimulation franchise and will eventually obtain approval for Virtis. O'Brien thinks risk-tolerant investors to take a look at the name here and he reiterates an Overweight rating on Nuvectra shares.
04/11/19
PIPR
04/11/19
NO CHANGE
PIPR
Piper sees Nuvectra, Boston Scientific as winners in spinal cord stimulation
After surveying 37 clinicians on the present and future treatment of low back pain, Piper Jaffray analyst Matt O'Brien believes the spinal cord stimulation market is poised to continue "growing quickly." While the survey indicated Nevro (NVRO) and Nuvectra (NVTR) would pick up market share this year, O'Brien believes Boston Scientific (BSX) and Nuvectra will be the "primary share-gainers."
05/02/19
PIPR
05/02/19
NO CHANGE
Target $18
PIPR
Overweight
Nuvectra selloff brings attractive entry point, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien is not overly surprised by the pushed out Virtis approval timeline and believes Nuvectra shares largely reflected the likelihood given how long it took to hear back from the FDA. On the positive side, the company's spinal cord stimulation momentum continues to demonstrate above market growth, which will be supported by salesforce expansion and a key MR full-body approval by Q4, O'Brien tells investors in a post-earnings research note. He believes today's selloff represents an attractive entry point for investors and keeps an Overweight rating on Nuvectra. O'Brien lowered his price target for the shares to $18 from $20.
MDSO Medidata
$94.75

3.97 (4.37%)

05/01/19
DOTC
05/01/19
DOWNGRADE
DOTC
Neutral
Medidata downgraded earlier to Neutral from Buy at Dougherty
04/30/19
PIPR
04/30/19
NO CHANGE
Target $96
PIPR
Overweight
Medidata price target raised to $96 from $83 at Piper Jaffray
Piper Jaffray analyst Sean Wieland raised his price target for Medidata to $96 from $83 and reiterated an Overweight rating after the company reported upside to EPS and revenue in Q1 and posted subscription backlog that offers 92% visibility on the rest of the year. Wieland tells investors in a research note that he is "excited" about Medidata's new Acornai AI offering, and notes that management commented on takeout speculation, saying that it would "do the right thing."
04/24/19
04/24/19
DOWNGRADE
Target $79

Hold
Medidata downgraded to Hold from Buy at SunTrust
As previously reported, SunTrust analyst Sandy Draper downgraded Medidata to Hold while keeping his $79 price target. The analyst cites his view of "limited upside from fundamentals or multiple expansion" for the stock, even though he remains "constructive" on the company's longer-term growth prospects. Draper adds that after a 30% year-to-date rally in the stock price, the fundamental outlook on the stock appears to be "fairly priced in", and while he assigns a $85-$100 per share potential takeout range, he lacks conviction that a transaction for Medidata will occur.
04/24/19
RHCO
04/24/19
DOWNGRADE
RHCO
Hold
Medidata downgraded to Hold from Buy at SunTrust
CBAY CymaBay
$6.05

-5.035 (-45.44%)

05/14/19
SBSH
05/14/19
INITIATION
Target $21
SBSH
Buy
CymaBay initiated with a Buy at Citi
Citi analyst Joel Beatty started CymaBay Therapeutics (CBAY) with a Buy rating and $21 price target. The analyst believes the company's seladelpar will "likely dethrone" Intercept Pharmaceuticals' (ICPT) Ocaliva as the top-selling branded primary biliary cholangitis drug. Topline results for seladelpar in PBC are anticipated in 2021 and the analyst sees a 75% probability of approval.
06/11/19
PIPR
06/11/19
NO CHANGE
Target $8
PIPR
Overweight
Piper cuts CymaBay price target to $8 on 'worst case' results for NASH trial
Piper Jaffray analyst Tyler Van Buren said he did not anticipate that placebo would perform better than seladelpar in CymaBay Therapeutics' (CBAY) Phase 2b study of the drug for the treatment of nonalcoholic steatohepatitis. Calling the NASH trial results a "worst case scenario," Van Buren sees significant risk to the final 52-week data read-out and removed all expectations in NASH from his model. He said the data make seladelpar seem similar to Genfit's (GNFT) elafibranor, though seladelpar has not yet shown improvements in good cholesterol, glucose homeostatis, or insulin resistance. While Van Buren cut his price target on CymaBay shares to $8 from $30 based on the trial results, he keeps an Overweight rating on the shares given the sharp pullback this morning and the support he sees from the company's remaining cash and residual opportunity.
06/11/19
RAJA
06/11/19
UPGRADE
Target $19
RAJA
Strong Buy
CymaBay upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Steven Seedhouse upgraded CymaBay to Strong Buy from Outperform citing the upside potential he sees following today's pullback in the stock. He keeps a $19 price target on the shares, calling today's reaction to the surrogate endpoint data "overblown."
06/07/19
LEER
06/07/19
NO CHANGE
Target $22
LEER
Outperform
FDA news has 'nothing to do' with CymaBay's programs, says SVB Leerink
SVB Leerink analyst Pasha Sarraf says that CymaBay Therapeutics is down on an "overreaction" to the FDA's recommendation regarding endpoint for compensated cirrhosis. In a research note to investors , Sarraf says he recommends purchasing at these levels, saying he continues to believe the the stock is likely to pop on the interim results from the MRI-PDFF results, which have not yet been announced and feels the FDA's announcement regarding compensated cirrhosis has "absolutely nothing to do" with CymaBay's programs. Sarraf has an Outperform rating and $22 price target on CymaBay shares.
TSLA Tesla
$217.08

4.18 (1.96%)

06/10/19
ROTH
06/10/19
UPGRADE
ROTH
Buy
Tesla upgraded to Buy from Neutral at Roth Capital
06/11/19
MSCO
06/11/19
NO CHANGE
Target $230
MSCO
Equal Weight
Tesla's Autonomy business underappreciated and undervalued, says Morgan Stanley
Morgan Stanley analyst Adam Jonas said efforts in recent years by auto companies such as General Motors (GM) and Ford (F) to focus on mobility have created a currency to attract and retain talent, created the opportunity for new partnerships out of the auto industry and increased the chances to bring in new capital and fund projects at "potentially far more attractive" costs. In this context, he thinks investors underappreciate and undervalue Tesla's Autonomy business, though he values the tech assets in the business at $45 per Tesla share. Given the elevated level of turnover of executives in recent quarters, he sees talent retention and continued access to capital as important priorities for Tesla, added Jonas, who keeps an Equal Weight rating and $230 price target on the stock.
06/10/19
06/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Buy from Neutral at Roth Capital with analyst Craig Irwin saying while he believes rising battery costs are likely to be a 2019 margin headwind, demand from China will likely be stronger than most anticipate, reducing the potential for lowered 2019 unit guidance. 2. Analog Devices (ADI) double upgraded to Buy from Sell at Goldman Sachs with analyst Toshiya Hari saying he is turning more bullish on the company as he believes analog units are tracking below trend. 3. United Technologies (UTX) upgraded to Buy from Neutral at Seaport Global with analyst Josh Sullivan saying at first glance, the company's merger-of-equals with Raytheon (RTN) offers a "compelling combination" in large defense and commercial aerospace growth verticals. 4. Adecoagro (AGRO) upgraded to Buy from Neutral at Citi with analyst Fernanda Perez Da Cunha citing the improvement in commodity prices and a slight reduction in long term maintenance capital expenditures for sugar and ethanol for the upgrade. 5. Sirius XM (SIRI) upgraded to Outperform from Neutral at Credit Suisse with analyst Brian Russo saying the stock decline has brought an attractive risk/reward opportunity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/10/19
06/10/19
UPGRADE
Target $238

Buy
Tesla upgraded to Buy on China demand at Roth Capital
As previously reported, Roth Capital analyst Craig Irwin upgraded Tesla to Buy from Neutral, with a $238 price target, after meetings with major Chinese EV producers and relevant supply chain participants. While the analyst believes rising battery costs are likely to be a 2019 margin headwind, demand from China will likely be stronger than most anticipate, reducing the potential for lowered 2019 unit guidance. China Model 3 deliveries of 2,324 units in May, after the initial 259 deliveries in April, suggest a "credible" second half of 2019 ramp, Irwin contends.
PLAY Dave & Buster's
$51.55

0.98 (1.94%)

04/03/19
MAXM
04/03/19
NO CHANGE
Target $67
MAXM
Buy
Dave & Buster's price target raised to $67 from $64 at Maxim
Maxim analyst Stephen Anderson raised his price target on Dave & Buster's to $67 and kept his Buy rating after its "triple-beat" Q4 results. The analyst notes that the quarter saw strong sales in the company's Amusements business as well as positive comps in its Food & Beverage business "for the first time in two years". While Anderson is lowering his Q1 earnings forecast by 1c to $1.15 to reflect Dave & Buster's higher costs associated with more aggressive unit openings, he also raises his FY19 earnings outlook to $3.25 from $3.15 after its announcement of an expanded $200M buyback program.
04/03/19
BMOC
04/03/19
NO CHANGE
Target $66
BMOC
Outperform
Dave & Buster's price target raised to $66 from $62 at BMO Capital
BMO Capital analyst Andrew Strelzik raised his price target on Dave & Buster's to $66 and kept his Outperform rating after its better than expected Q4 results, with earnings, comps, revenue, and margins all exceeding the high end of guidance offered in January. The analyst notes that the company's FY19 outlook was below consensus at the midpoint, but it is likely to be "perceived as conservative", adding the investor focus will now shift to whether Dave & Buster's "can maintain positive trajectory as it laps initial virtual reality launch in Q2".
03/05/19
RHCO
03/05/19
NO CHANGE
Target $61
RHCO
Buy
Dave & Buster's price target lowered to $61 from $69 at SunTrust
SunTrust analyst Jake Bartlett lowered his price target on Dave & Buster's to $61, saying his competitive analysis work suggests that the company is faced with "continued headwinds" from "smaller 'eatertainment' chains and 2 other potential threats". The analyst believes that the combined 31 new location unit growth at Main Event, Punch Bowl Social, Round 1 USA, and Topgolf competitors will impact Dave & Buster's FY19 comps by about 150bps, with added SSS headwinds coming from the large and rapidly growing chains - Bowlero and Urban Air trampoline park. Longer term, Bartlett is keeping his Buy rating on Dave & Buster's shares, expecting the chain to "remain one of the fastest growing restaurants" and to "re-accelerate SSS as it improves its gaming content and food and beverage offering".
01/16/19
MAXM
01/16/19
NO CHANGE
Target $64
MAXM
Buy
Maxim raises Dave & Buster's Q4 earnings outlook
Maxim analyst Stephen Anderson kept his Buy rating and $64 price target on Dave & Buster's while raising his outlook for Q4 earnings to 67c from 65c after the release of the company's better than expected holiday sales comps. The analyst cites the company's view of the holiday season as strong, helped by the launch of the new VR game Dragonfrost.
FIZZ National Beverage
$45.15

-2.3 (-4.85%)

06/11/19
06/11/19
DOWNGRADE

National Beverage downgraded to Hold from Buy at CFRA Research
CFRA Research downgraded National Beverage to Hold from Buy with a $50 price target on shares of the parent of the Lacroix sparkling water brand.
06/04/19
06/04/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Netflix (NFLX) upgraded to Buy from Hold at Loop Capital with analyst Alan Gould saying Netflix has built an "unstoppable lead" in subscription video streaming while the company's margin opportunity is expanding as it increasingly becomes a content producer, distributor and retailer. 2. Wingstop (WING) upgraded to Buy from Hold at Stifel with analyst Chris O'Cull saying the company's system sales growth will remain in mid to high teens for the foreseeable future and generate higher cash flows from increased average unit volumes thanks to its national advertising and digital ordering initiatives. 3. National Beverage (FIZZ) upgraded to Neutral from Sell at UBS with analyst Sean King citing valuation. 4. Take-Two (TTWO) upgraded to Market Perform from Underperform at BMO Capital with analyst Gerrick Johnson with the threat of an economic downturn, video game stocks will be increasingly seen as "safe havens for investors." 5. Mirati Therapeutics (MRTX) upgraded to Buy from Neutral at Citi with analyst Yigal Nochomovitz saying he believes Mirati's KRAS G12Ci has potential to exceed AMG510's 50% overall response rate in non-small cell lung cancer. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/04/19
UBSW
06/04/19
UPGRADE
Target $48
UBSW
Neutral
National Beverage upgraded to Neutral from Sell at UBS
UBS analyst Sean King upgraded National Beverage to Neutral from Sell while lowering his price target for the shares to $48 from $50. The analyst cites valuation for the upgrade following the "steep" correction in the shares. The stock price now adequately discounts challenges for the company's flagship LaCroix, King tells investors in a research note. The analyst sees a more balanced risk/reward at current valuation levels and believes National Beverage's trends "may be bottoming on weather and tough compares."
06/03/19
MAXM
06/03/19
UPGRADE
MAXM
Hold
National Beverage upgraded to Hold from Sell at Maxim
Maxim analyst Anthony Vendetti upgraded National Beverage to Hold from Sell following the significant fall in its shares from their highs, which he mainly attributes to declining growth in its LaCroix brand.

TODAY'S FREE FLY STORIES

VTR

Ventas

$69.65

1.05 (1.53%)

21:28
06/19/19
06/19
21:28
06/19/19
21:28
Upgrade
Ventas rating change at Stifel »

Stifel upgrades to Ventas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$197.87

-0.65 (-0.33%)

21:22
06/19/19
06/19
21:22
06/19/19
21:22
Initiation
Apple initiated at Deutsche Bank »

Apple initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

DELL

Dell Technologies

$53.39

1.88 (3.65%)

21:22
06/19/19
06/19
21:22
06/19/19
21:22
Initiation
Dell Technologies initiated at Deutsche Bank »

Dell Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

HPQ

HP Inc.

$20.63

0.1 (0.49%)

21:21
06/19/19
06/19
21:21
06/19/19
21:21
Initiation
HP Inc. initiated at Deutsche Bank »

HP Inc. initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

GNCA

Genocea

$3.84

-1.32 (-25.58%)

21:18
06/19/19
06/19
21:18
06/19/19
21:18
Syndicate
Genocea 10M share Secondary priced at $3.50 »

SVB Leerink and Stifel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

PSNL

Personalis

$0.00

(0.00%)

21:15
06/19/19
06/19
21:15
06/19/19
21:15
Syndicate
Personalis 7.922M share IPO priced at $17.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CYRX

Cryoport

$18.62

-0.08 (-0.43%)

21:13
06/19/19
06/19
21:13
06/19/19
21:13
Syndicate
Cryoport 3.75M share Spot Secondary priced at $17.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

VTR

Ventas

$69.65

1.05 (1.53%)

20:41
06/19/19
06/19
20:41
06/19/19
20:41
Upgrade
Ventas rating change at Stifel »

Ventas upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSY

Hershey

$137.94

-0.29 (-0.21%)

20:27
06/19/19
06/19
20:27
06/19/19
20:27
Downgrade
Hershey rating change at Piper Jaffray »

Hershey downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KR

Kroger

$23.64

-0.3 (-1.25%)

, DRI

Darden

$117.55

-0.39 (-0.33%)

20:25
06/19/19
06/19
20:25
06/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KR

Kroger

$23.64

-0.3 (-1.25%)

DRI

Darden

$117.55

-0.39 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 25

    Jun

  • 27

    Jun

DAL

Delta Air Lines

$56.38

0.33 (0.59%)

20:08
06/19/19
06/19
20:08
06/19/19
20:08
Periodicals
Breaking Periodicals news story on Delta Air Lines »

Delta working on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

SPY

SPDR S&P 500 ETF Trust

$293.02

0.69 (0.24%)

, SPX

S&P 500

$0.00

(0.00%)

20:00
06/19/19
06/19
20:00
06/19/19
20:00
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

Trump not planning to…

SPY

SPDR S&P 500 ETF Trust

$293.02

0.69 (0.24%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARZGY

Generali

$0.00

(0.00%)

19:22
06/19/19
06/19
19:22
06/19/19
19:22
Downgrade
Generali rating change at JPMorgan »

Generali downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GO

Grocery Outlet

$0.00

(0.00%)

19:00
06/19/19
06/19
19:00
06/19/19
19:00
Syndicate
Grocery Outlet 17.19M share IPO priced at $22.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

WIX

Wix.com

$145.83

1.19 (0.82%)

18:57
06/19/19
06/19
18:57
06/19/19
18:57
Hot Stocks
Wix.com CEO: Q1 was very good for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AOBC

American Outdoor Brands

$9.17

0.13 (1.44%)

, ORCL

Oracle

$52.69

-0.19 (-0.36%)

18:44
06/19/19
06/19
18:44
06/19/19
18:44
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

AOBC

American Outdoor Brands

$9.17

0.13 (1.44%)

ORCL

Oracle

$52.69

-0.19 (-0.36%)

JSYN

Jensyn Acquisition

$5.00

-5.02 (-50.10%)

ABEO

Abeona Therapeutics

$4.90

-0.09 (-1.80%)

PIR

Pier 1 Imports

$0.67

-0.0059 (-0.87%)

SCS

Steelcase

$17.80

0.235 (1.34%)

LAND

Gladstone Land

$12.29

0.39 (3.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 20

    Jun

  • 24

    Jun

  • 26

    Jun

  • 26

    Jun

  • 10

    Jul

  • 20

    Jun

TMUS

T-Mobile

$78.28

1.79 (2.34%)

, S

Sprint

$7.46

0.24 (3.32%)

18:39
06/19/19
06/19
18:39
06/19/19
18:39
Periodicals
T-Mobile readies for Boost auction if Dish talks fall through, Reuters says »

T-Mobile (TMUS) is…

TMUS

T-Mobile

$78.28

1.79 (2.34%)

S

Sprint

$7.46

0.24 (3.32%)

DISH

Dish

$38.90

-0.18 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$200.57

-1.1 (-0.55%)

18:39
06/19/19
06/19
18:39
06/19/19
18:39
Hot Stocks
Zebra Technologies Chief of Product sells 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$200.57

-1.1 (-0.55%)

18:23
06/19/19
06/19
18:23
06/19/19
18:23
Hot Stocks
Zebra Technologies CEO sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$250.25

4.6 (1.87%)

, DVA

DaVita

$51.27

1.51 (3.03%)

18:13
06/19/19
06/19
18:13
06/19/19
18:13
Hot Stocks
FTC approves UnitedHealth's acquisition of DaVita Medical with conditions »

Healthcare provider and…

UNH

UnitedHealth

$250.25

4.6 (1.87%)

DVA

DaVita

$51.27

1.51 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

SRRK

Scholar Rock

$17.11

-2.835 (-14.21%)

18:11
06/19/19
06/19
18:11
06/19/19
18:11
Syndicate
Scholar Rock 3M share Secondary priced at $15.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

QDEL

Quidel

$58.80

1.7 (2.98%)

18:01
06/19/19
06/19
18:01
06/19/19
18:01
Hot Stocks
Quidel receives 510k clearance for Triage TOX Drug Screen »

Quidel Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$53.39

1.88 (3.65%)

, HPQ

HP Inc.

$20.63

0.1 (0.49%)

17:59
06/19/19
06/19
17:59
06/19/19
17:59
Periodicals
Dell, HP, Intel, Microsoft express opposition to Trump tariffs, Bloomberg says »

Dell Technologies (DELL),…

DELL

Dell Technologies

$53.39

1.88 (3.65%)

HPQ

HP Inc.

$20.63

0.1 (0.49%)

INTC

Intel

$47.08

-0.29 (-0.61%)

MSFT

Microsoft

$135.63

0.43 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 23

    Jun

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

  • 09

    Jul

  • 09

    Jul

  • 10

    Jul

  • 25

    Jul

  • 06

    Aug

ORCL

Oracle

$52.69

-0.19 (-0.36%)

17:54
06/19/19
06/19
17:54
06/19/19
17:54
Hot Stocks
Oracle says 20% of Autonomous Database customers new to company »

Says plans to launch free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

CB

Chubb

$149.48

1.37 (0.92%)

17:54
06/19/19
06/19
17:54
06/19/19
17:54
Hot Stocks
Chubb CEO sells 215.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.